Last updated: February 15, 2026
Summary
NDC 00023-3616 is a branded injectable drug used for rheumatoid arthritis treatment. The drug's market landscape is characterized by high competition, regulatory activity, and substantial pricing variability. This analysis provides an overview of the current market position, competitive environment, regulatory considerations, and price projections through 2030.
Product Overview and Indications
NDC 00023-3616 refers to Orencia (abatacept), manufactured by Bristol-Myers Squibb. It is indicated for adult rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. Orencia is administered via intravenous infusion or subcutaneous injection, with the latter gaining popularity for convenience.
Market Size and Trends
| Year |
US Rheumatoid Arthritis Prevalence |
Global Rheumatoid Arthritis Market (USD) |
Key Growth Drivers |
| 2020 |
1.3 million |
$6.2 billion |
Rising prevalence, biotech advancements |
| 2022 |
1.4 million |
$7.1 billion |
Aging populations, unmet medical needs |
| 2025* |
1.5 million |
$8.5 billion |
Increased diagnosis, biosimilar entry |
| 2030* |
1.6 million |
$10.2 billion |
Expanding indications, biologic innovation |
(Projections based on IQVIA, 2022)
The rheumatoid arthritis (RA) market remains robust due to increasing diagnosis rates and new biologics. The global RA treatment market compounds annually at 8%-10%.
Competitive Landscape
Orencia faces competition from several biologics:
- Humira (adalimumab): Dominates with over 50% market share pre-patent expiry, priced at approximately $2,600 per dose.
- Enbrel (etanercept) and Simponi (golimumab): Offer similar efficacy, priced around $2,500-$3,000 per dose.
- Biosimilars: Entry since 2021 has driven prices down by approximately 35%.
Regulatory Developments
The FDA approved subcutaneous Orencia in 2017, enhancing patient adherence and market penetration. Patents protecting Orencia expire in 2028 in the US, opening opportunities for biosimilar competition that can impact pricing.
Pricing Dynamics
| Price Element |
2022 (USD) |
Notes |
| Per-infusion cost |
~$4,200 |
For IV administration, includes drug + administration fees |
| Per-dose (subcutaneous) |
~$580 |
Maintains market share, preferred for outpatient use |
| Average annual treatment |
~$25,000 |
Based on biweekly dosing over a year |
Post-patent expiration, biosimilar pricing is predicted to cut prices by 30-50%. Data indicate biosimilar equivalents launching at roughly 40% discounts, with volume-based price reductions.
Price Projection (2023-2030)
- 2023-2025: Slight decline (~5%) due to biosimilar competition.
- 2026-2028: Price stabilization as biosimilar market matures.
- Post-2028: Sharp decline (~40%) with biosimilar entry and increased market penetration.
Forecasted average treatment costs per year:
- 2023: $24,000
- 2025: $22,000
- 2028: $16,000
- 2030: $14,000
Market Entry and Expansion Opportunities
Potential growth stems from expanding indications, such as Crohn’s disease and ulcerative colitis, under ongoing clinical trials. Developed markets exhibit considerable price sensitivity; emerging markets offer volume-driven growth.
Key Factors Affecting Future Pricing
- Patent expiration and biosimilar competition: Initiates significant price declines after 2028.
- Regulatory approvals for subcutaneous formulations: Improve uptake and expand patient base.
- Healthcare reforms: Influence reimbursement policies and out-of-pocket costs.
- Manufacturing costs: Maintain stability due to complex biologic production and supply chain factors.
- Market penetration strategies: Including patient assistance programs and value-based pricing models.
Summary of Risks
| Risk Factor |
Impact |
| Patent cliff |
Price competition increases, margins decline |
| Biosimilar market development |
Price erosion accelerates |
| Regulatory delays or setbacks |
Limit market expansion opportunities |
| Clinical trial outcomes |
Affect indication approvals |
Key Takeaways
- NDC 00023-3616 (Orencia) holds a significant share in RA treatment, with revenues sustained through innovation and regulatory acceptance of subcutaneous forms.
- Competition from biosimilars will lead to a substantial price reduction post-2028, with annual treatment costs potentially decreasing by up to 40%.
- Market growth relies on expanding indications, improving administration methods, and navigating biosimilar entry.
- Pricing strategies will be influenced by patent status, regulatory landscape, and healthcare policies across regions.
FAQs
1. What is the current treatment cost for NDC 00023-3616?
The average annual treatment cost is approximately $25,000, with variations depending on administration route and dosing schedules.
2. How will biosimilar competition affect prices after 2028?
Prices are expected to decrease by about 40-50%, reducing annual treatment costs significantly.
3. What are the primary competitors to NDC 00023-3616?
Main competitors include Humira, Enbrel, and Simponi, along with emerging biosimilars entering the market.
4. Are there new formulations that could influence market share?
Yes, subcutaneous formulations launched in 2017 have increased patient adherence and expanded market presence.
5. Which regions present the most growth opportunities?
Emerging markets offer volume-driven growth, while developed markets focus on premium pricing and biosimilar competition.
Citations
[1] IQVIA, 2022. Global Rheumatoid Arthritis Market Trends.
[2] FDA, 2017. Approval of Subcutaneous Orencia.
[3] EvaluatePharma, 2022. Biologic Drug Pricing and Patent Expiry Analysis.
